152 results on '"Moriwaki, Hisataka"'
Search Results
2. Revised criteria for classification of the etiologies of acute liver failure and late-onset hepatic failure in Japan: A report by the Intractable Hepato-biliary Diseases Study Group of Japan in 2015
3. Preventive effects of astaxanthin on diethylnitrosamine-induced liver tumorigenesis in C57/BL/KsJ-db/db obese mice
4. Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac-2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis
5. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial
6. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial
7. Free fatty acid as a marker of energy malnutrition in liver cirrhosis
8. Effects of branched-chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis
9. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study
10. Nutritional status and quality of life in current patients with liver cirrhosis as assessed in 2007–2011
11. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
12. Timing of interferon therapy and sources of infection in patients with acute hepatitis C
13. Combination of acyclic retinoid with branched-chain amino acids inhibits xenograft growth of human hepatoma cells in nude mice
14. Guidelines on nutritional management in Japanese patients with liver cirrhosis from the perspective of preventing hepatocellular carcinoma
15. Guideline on the use of new anticancer drugs for the treatment of Hepatocellular Carcinoma 2010 update
16. Novel scoring system as a useful model to predict the outcome of patients with acute liver failure: Application to indication criteria for liver transplantation
17. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
18. Nutritional status and long-term outcome of viral liver cirrhosis: Luncheon Seminar 2 by Ajinomoto Pharma
19. Insulin resistance raises the risk for recurrence of stage I hepatocellular carcinoma after curative radiofrequency ablation in hepatitis C virus-positive patients: A prospective, case series study
20. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
21. Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
22. Pathological role of CD44 on NKT cells in carbon tetrachloride-mediated liver injury
23. Prospective study on early virologic response to treatment with interferon α-2b plus ribavirin in patients with chronic hepatitis C genotype 1b
24. Clinical comparison of branched-chain amino acid ( l-Leucine, l-Isoleucine, l-Valine) granules and oral nutrition for hepatic insufficiency in patients with decompensated liver cirrhosis (LIV–EN study)
25. Liver injury induced by lipopolysaccharide is mediated by TNFR-1 but not by TNFR-2 or Fas in mice
26. Long-term outcome of branched-chain amino acid treatment in patients with liver cirrhosis
27. Implication of cytokines: Roles of tumor necrosis factor-α in liver injury
28. Transcription factor HNF and hepatocyte differentiation
29. Significant effect of hepatitis C virus specific CTLs on viral clearance in patients with type C chronic hepatitis treated with antiviral agents
30. Chemoprevention of liver carcinogenesis with retinoids: Basic and clinical aspects
31. Oral branched-chain amino acid supplementation improves the oxidized/reduced albumin ratio in patients with liver cirrhosis
32. Inhibition of nuclear factor-kappa B induces inflammatory cell migration and exacerbates severe liver injury in hepatitis B virus transgenic mice
33. Nocturnal energy and BCAA supplementation in patients with liver cirrhosis
34. Metabolic disorders in patients with liver cirrhosis
35. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex‐stratified analysis
36. Hypozincemia is associated with human hepatocarcinogenesis in hepatitis C virus‐related liver cirrhosis
37. Improvement of fuel metabolism by nocturnal energy supplementation in patients with liver cirrhosis
38. Both insulin sensitivity and glucose sensitivity are impaired in patients with non-diabetic liver cirrhosis
39. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis
40. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial
41. Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis.
42. Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients
43. Rapid skeletal muscle wasting predicts worse survival in patients with liver cirrhosis
44. Preventive effects of astaxanthin on diethylnitrosamine-induced liver tumorigenesis in C57/BL/KsJ-db/dbobese mice
45. Carnitine dynamics and their effects on hyperammonemia in cirrhotic Japanese patients.
46. Efficacy and safety of cisplatin versus miriplatin in transcatheter arterial chemoembolization and transarterial infusion chemotherapy for hepatocellular carcinoma: A randomized controlled trial
47. Open-labeled randomized controlled trial to compare diuretic therapy with recombinant human serum albumin and diuretic therapy for therapeutic treatment of ascites in patients with advanced liver cirrhosis: An exploratory trial
48. Free fatty acid as a marker of energy malnutrition in liver cirrhosis
49. Effects of branched‐chain amino acid granules on serum albumin level and prognosis are dependent on treatment adherence in patients with liver cirrhosis
50. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open‐label study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.